ArticleJournal of diabetes2019
Renoprotective effects of brown adipose tissue activation in diabetic mice.
Article in Journal of diabetes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Role of miR-34a/KLF4 axis in podocyte injury and obesity-related glomerulopathy with preliminary observations in clear cell renal cell carcinoma.Current urology · 2026Article
- ST32da, a NovelCells · 2025Article
- Modeling Adipokine and Insulin-Mediated Crosstalk Between Adipocytes and Beta Cells Using Flow-Enabled Microfluidics.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Asiatic Acid Alleviates Renal Damage by Upregulating STBD1-Mediated Glycophagy in Diabetic Kidney Disease.Biomedicines · 2025Article
- Discussion on the treatment of diabetic kidney disease based on the "gut-fat-kidney" axis.International urology and nephrology · 2025Review
- Asprosin Levels in Adults with Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Systematic Review and Meta-Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- The Role of Sirtuins in Diabetic Nephropathy: A Comprehensive Review.Current protein & peptide science · 2025Review
- Adiponectin-induced activation of ERK1/2 drives fibrosis in retinal pigment epithelial cells.Human cell · 2024Article
- UCP1 expression in human brown adipose tissue is inversely associated with cardiometabolic risk factors.European journal of endocrinology · 2024Article
- Molecular Challenges and Opportunities in Climate Change-Induced Kidney Diseases.Biomolecules · 2024Review
- Plasma Asprosin Concentrations are Associated with Progression of Diabetic Kidney Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Treatment of obesity-related diabetes: significance of thermogenic adipose tissue and targetable receptors.Frontiers in pharmacology · 2023Review
- PGC1Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
- Review
- Long noncoding RNA XIST regulates brown preadipocytes differentiation and combats high-fat diet induced obesity by targeting C/EBPα.Molecular medicine (Cambridge, Mass.) · 2022Article
- SIRT1-SIRT7 in Diabetic Kidney Disease: Biological Functions and Molecular Mechanisms.Frontiers in endocrinology · 2022Review
- Sirtuin Family and Diabetic Kidney Disease.Frontiers in endocrinology · 2022Review
- Regulation of Adipose Thermogenesis and its Critical Role in Glucose and Lipid Metabolism.International journal of biological sciences · 2022Review
- The Multiple Roles of Fibroblast Growth Factor in Diabetic Nephropathy.Journal of inflammation research · 2021Review
- Transplantation of brown adipose tissue up-regulates miR-99a to ameliorate liver metabolic disorders in diabetic mice by targeting NOX4.Adipocyte · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundBrown adipose tissue (BAT) has been regarded as a potential target organ to combat obesity and related metabolic disorders. However, the effect of BAT activation on the development of diabetic kidney disease (DKD) remains unclear.
methodsDiabetic mice were induced by streptozotocin (STZ) combined with a high-fat diet. To activate BAT, mice were administered 1 mg/kg per day, i.p., CL316,243, a β
resultsCompared with untreated STZ-diabetic mice, CL316,243 treatment reduced blood glucose, albeit not significantly (20.58 ± 3.55 vs 23.60 ± 3.90 mM), and significantly decreased triglycerides and low-density lipoprotein cholesterol and increased high-density lipoprotein cholesterol. Simultaneously, BAT activation significantly decreased 24-hour urinary albumin (34.21 ± 6.28 vs 70.46 ± 15.81 μg/24 h; P < 0.05) and 8-OHdG, improved renal fibrosis, inflammation, and oxidative stress, and ameliorated renal morphological abnormalities. In addition to enhancing BAT activity, CL316,243 significantly increased serum adiponectin concentrations and renal Fgf21 sensitivity, and reactivated the renal AMPK/Sirt1/Pgc1α signaling pathway. Furthermore, CL316,243 treatment increased levels of some circulating miRNAs and downregulated expression of their target genes in the kidney.
conclusionsActivating BAT could improve kidney injury in diabetic mice via metabolic improvements and renal AMPK activation by beneficial adipokines and miRNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.